TRAIL-induced apoptosis : between tumor therapy and immunopathology

Cite This

Files in this item

Checksum: MD5:19b32cff03da3e2ffd15e27952ab5b11

CORAZZA, Nadia, Daniela KASSAHN, Sabine JAKOB, Anastasia BADMANN, Thomas BRUNNER, 2009. TRAIL-induced apoptosis : between tumor therapy and immunopathology. In: Annals of the New York Academy of Sciences. 1171(1), pp. 50-58. ISSN 0077-8923. eISSN 1749-6632. Available under: doi: 10.1111/j.1749-6632.2009.04905.x

@article{Corazza2009-08TRAIL-14347, title={TRAIL-induced apoptosis : between tumor therapy and immunopathology}, year={2009}, doi={10.1111/j.1749-6632.2009.04905.x}, number={1}, volume={1171}, issn={0077-8923}, journal={Annals of the New York Academy of Sciences}, pages={50--58}, author={Corazza, Nadia and Kassahn, Daniela and Jakob, Sabine and Badmann, Anastasia and Brunner, Thomas} }

<rdf:RDF xmlns:dcterms="" xmlns:dc="" xmlns:rdf="" xmlns:bibo="" xmlns:dspace="" xmlns:foaf="" xmlns:void="" xmlns:xsd="" > <rdf:Description rdf:about=""> <bibo:uri rdf:resource=""/> <dc:rights>terms-of-use</dc:rights> <dcterms:title>TRAIL-induced apoptosis : between tumor therapy and immunopathology</dcterms:title> <dcterms:available rdf:datatype="">2011-10-26T07:43:35Z</dcterms:available> <dcterms:rights rdf:resource=""/> <dspace:isPartOfCollection rdf:resource=""/> <dc:contributor>Badmann, Anastasia</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dcterms:issued>2009-08</dcterms:issued> <dc:creator>Brunner, Thomas</dc:creator> <dc:date rdf:datatype="">2011-10-26T07:43:35Z</dc:date> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>Jakob, Sabine</dc:contributor> <dc:creator>Corazza, Nadia</dc:creator> <dc:creator>Kassahn, Daniela</dc:creator> <dc:contributor>Kassahn, Daniela</dc:contributor> <dcterms:hasPart rdf:resource=""/> <dc:creator>Jakob, Sabine</dc:creator> <dspace:hasBitstream rdf:resource=""/> <dc:contributor>Brunner, Thomas</dc:contributor> <dcterms:abstract xml:lang="eng">The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.</dcterms:abstract> <dc:creator>Badmann, Anastasia</dc:creator> <dc:language>eng</dc:language> <dcterms:isPartOf rdf:resource=""/> <dc:contributor>Corazza, Nadia</dc:contributor> <dcterms:bibliographicCitation>First publ. in: Annals of the New York Acadamy of Sciences ; 1171 (2009). - pp. 50-58</dcterms:bibliographicCitation> </rdf:Description> </rdf:RDF>

Downloads since Oct 1, 2014 (Information about access statistics)

Corazza_ANYACAD_09.pdf 635

This item appears in the following Collection(s)

Search KOPS


My Account